K
Kardium
Develops medical devices for the diagnosis and treatment of atrial fibrillation
About Kardium
Kardium is a medical device company specializing in the treatment of atrial fibrillation, a common heart rhythm disorder affecting over 37 million people globally. The company's core product, the Globe System, integrates high-definition anatomical and electrical mapping with radio frequency energy delivery to isolate pulmonary veins and ablate atrial tissue. This comprehensive solution is designed for cardiologists and electrophysiologists, offering a single device for multiple procedures. Kardium operates in the medical technology market, primarily targeting healthcare providers and institutions. The business model revolves around the sale of its advanced catheter systems and related services, generating revenue through direct sales and long-term contracts with medical facilities. The company is headquartered in greater Vancouver, Canada, and boasts a team of experts in medicine, engineering, and business.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Burnaby, Canada
- Employees
- 636
- Open positions
- 60
- Dealroom signal
- 96.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Spinout, Tech for Hospitals and Clinics, Rumoured $1B, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Kardium.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2025 | $250M | $1B | T. Rowe Price · Durable Capital Partners · Qatar Investment Authority · Eventide Asset Management | ↗ |
| LATE VCOther financing | Jun 2024 | $104M | $416M | T. Rowe Price · Durable Capital Partners · Fidelity Investments | ↗ |
Growth signals
Latest recorded traffic for Kardium is 16K monthly website visits, up 0% over the last three months. Kardium's team grew 29.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Research Council Canada
PacifiCan
Series B and later9 investors entered at this stage
Conconi Growth Partners
T. Rowe Price
Fidelity Investments
Durable Capital Partners
Qatar Investment Authority
Eventide Asset Management
Janus Henderson Investors- PCPiper Heartland Healthcare Capital
Ekuity Capital
Other known investors1 additional known investor
The University of British Columbia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kardium on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kardium’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.